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ABSTRACT
Introduction Cerebral small- vessel disease is common 
in neurologically asymptomatic individuals with type 1 
diabetes. The retinal vasculature is thought to mirror the 
brain’s vasculature, but data on this association are limited 
in type 1 diabetes. Our aim was to study associations 
between diabetic retinopathy severity and cerebral small- 
vessel disease in type 1 diabetes.
Research design and methods For this cross- sectional 
study, we enrolled 189 participants with type 1 diabetes 
(median age 40 (33–45) years; 53% female; diabetes 
duration 21.6 (18.2–30.7) years) and 29 healthy age- 
matched and sex- matched controls as part of the Finnish 
Diabetic Nephropathy Study. Participants underwent a 
clinical investigation, brain MRI, and fundus imaging. 
Signs of cerebral small- vessel disease in brain MRIs were 
analyzed in relation to diabetic retinopathy severity (Early 
Treatment Diabetic Retinopathy Study (ETDRS) score).
Results In type 1 diabetes, participants with cerebral 
small- vessel disease had higher ETDRS scores (35 
(20–61) vs 20 (20–35), p=0.022) and a higher prevalence 
of proliferative diabetic retinopathy than those without 
cerebral small- vessel disease (25% vs 9%, p=0.002). 
In adjusted analysis, proliferative diabetic retinopathy 
was associated with cerebral small- vessel disease 
(OR 2.57 (95% CI 1.04 to 6.35)). Median ETDRS score 
(35 (20–65) vs 20 (20–35), p=0.024) and proliferative 
diabetic retinopathy prevalence were higher (29% vs 13%, 
p=0.002) in participants with versus without cerebral 
microbleeds. ETDRS scores increased by number of 
cerebral microbleeds (p=0.001), both ETDRS score (OR 
1.05 (95% CI 1.02 to 1.09)) and proliferative diabetic 
retinopathy (8.52 (95% CI 1.91 to 37.94)) were associated 
with >2 cerebral microbleeds in separate multivariable 
analysis. We observed no association with white matter 
hyperintensities or lacunar infarcts.
Conclusions Presence of cerebral small- vessel disease 
on brain MRI, particularly cerebral microbleeds, is 
associated with the severity of diabetic retinopathy.
BACKGROUND
Compared with healthy individuals, those 
with type 1 diabetes have an increased risk 
of circulatory disorders of the brain, such 
as stroke.1 In young individuals with type 1 
diabetes, more than half of the cases of stroke 
are of microvascular etiology, whereas the 
corresponding number is below 15% in the 
general population.2 Furthermore, type 1 
diabetes is thought to cause organ damage to 
the central nervous system in similarity with, 
and in association with, other diabetic organ 
damage.3
Disease of the microvasculature (arteri-
oles, capillaries, and venules) in the central 
nervous system is termed cerebral small- vessel 
disease, with the two most common aetiol-
ogies being hypertensive vasculopathy and 
cerebral amyloid angiopathy. Since the vascu-
lature is too microscopic to image in vivo per 
se, proxies for the disease are evaluated by 
MRI. Signs of cerebral small- vessel disease 
on MRI include lacunar infarcts, white 
matter hyperintensities, cerebral microbleeds 
(CMBs), and cortical superficial siderosis.4 5 
Significance of this study
What is already known about this subject?
 ► Cerebral small- vessel disease is common in neu-
rologically asymptomatic individuals with type 1 
diabetes.
 ► The retinal vasculature is thought to mirror the 
brain’s vasculature.
What are the new findings?
 ► Diabetic retinopathy severity is associated with ce-
rebral small- vessel disease in neurologically asymp-
tomatic individuals with type 1 diabetes.
 ► Of the different manifestations of cerebral small- 
vessel disease, especially the number of cerebral 
microbleeds increases with higher Early Treatment 
Diabetic Retinopathy Study score.
How might these results change the focus of 
research or clinical practice?
 ► Further investigations are needed to confirm these 
associations and their utility in clinical settings.
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In type 1 diabetes, only a few studies have assessed cere-
bral small- vessel disease more comprehensively, including 
the above- mentioned manifestations, with brain MRI.6–8 
We have preciously studied these markers and showed 
that cerebral small- vessel disease, especially microbleeds, 
is more common in type 1 diabetes than in the general 
population.6
Whereas cerebral small- vessel disease in vivo can only 
be studied indirectly by MRI,4 the vasculature of the eye 
is easily visible and can be directly and non- invasively 
studied by retinal fundus photography.9 The retina has 
often been proposed to act as a window into the brain, 
reflecting the burden of small- vessel disease, with the 
hypothesis that disrupted cerebral small vasculature 
would be mirrored in the retina.10 11 Retinopathy is prev-
alent in diabetes, being the most frequent microvascular 
complication, with retinal changes developing in up 
to 90% of individuals with type 1 diabetes, and 40% of 
type 2 diabetes.12 13 In type 2 diabetes, individuals with 
diabetic retinopathy have a higher prevalence of small- 
vessel disease markers, white matter hyperintensities, and 
lacunar infarcts, than subjects without diabetic retinop-
athy. Furthermore, small- vessel disease severity increases 
with age and presence of diabetic retinopathy in these 
individuals.14 In the general population, abnormalities of 
the retinal vasculature have also been linked to cerebral 
small- vessel disease, especially white matter hyperintensi-
ties and lacunar stroke.10 15
In type 1 diabetes, both cerebral small- vessel disease 
and diabetic retinopathy are common findings already at 
a rather young age, in contrast to that observed in the 
general population or type 2 diabetes.6 14 Despite this, 
data on the relationship between cerebral small- vessel 
disease and diabetic retinopathy in type 1 diabetes are 
scarce, and studies show contradictory results.6 8 16 17 The 
association between cerebral small- vessel disease and reti-
nopathy based on fundus images (in contrary to medical 
records or questionnaires) has been assessed in only one 
previous study, which found CMBs to be associated with 
proliferative diabetic retinopathy (PDR).8
Furthermore, there are no reports on the association 
between milder retinopathy than PDR and cerebral 
small- vessel disease in type 1 diabetes, and thus, it is yet 
unclear to what extent the overall severity of diabetic reti-
nopathy is associated with microvascular abnormalities 
of the brain. Hence, we aimed to study the association 
between diabetic retinopathy assessed by the Early Treat-
ment Diabetic Retinopathy Study (ETDRS) scale, and 
cerebral small- vessel disease in neurologically asymptom-
atic individuals with type 1 diabetes.
MATERIALS AND METHODS
Study participants
As part of the nationwide Finnish Diabetic Nephropathy 
(FinnDiane) Study, in 2010 we initiated a substudy at the 
Helsinki University Hospital study center, with the aim 
to identify early risk factors for cerebrovascular disease 
in type 1 diabetes. The FinnDiane Study,18 as well as the 
protocol of the recent substudy, has previously been 
described in detail.6 Inclusion criteria were age 18–50 
years and type 1 diabetes onset <40 years. Exclusion 
criteria were end- stage renal disease, previous clinical 
signs of cerebrovascular disease, and contraindications 
for MRI. In 2011–2017, all study participants underwent 
brain MRI. Of the 191 participants with type 1 diabetes 
and 30 healthy age- matched and sex- matched controls 
originally enrolled for the study, we obtained data from 
fundus images for 189 (99%) and 29 (97%) participants, 
respectively, all eligible for this study.
The study participants with type 1 diabetes had a 
median age of 40 (IQR 33–45) years, median duration of 
diabetes of 21.6 (18.2–30.7) years, and 101 (53%) were 
women. None of the participants had a history of coro-
nary heart disease or peripheral arterial disease.
Methods
All participants had a thorough evaluation of their 
medical history, such as diabetic complications, with 
data verified from participants’ medical records. Current 
medication, anthropometrics, and office blood pressure 
were recorded, and participants filled in questionnaires 
on lifestyle, including smoking.
Glycated hemoglobin (HbA1c), creatinine, total choles-
terol, low- density lipoprotein- cholesterol, high- density 
lipoprotein- cholesterol, and triglycerides were deter-
mined from blood samples. Glomerular filtration rate was 
calculated based on the Chronic Kidney Disease Epide-
miology Study formula.19 Furthermore, 24- hour urine 
samples were collected for determination of albumin 
excretion. Albuminuria was defined as urinary albumin 
excretion rate ≥20 µg/min or ≥30 mg/24 hours in two out 
of three urine collections. Blood and urine samples were 
analyzed in the central laboratory of the Helsinki Univer-
sity Hospital.
Brain MRI was performed with a 3.0 Tesla scanner 
(Achieva, Philips, Best, The Netherlands) at the Helsinki 
Medical Imaging Center, Helsinki University Hospital. 
MRIs were assessed according to standardized criteria5 20 
for markers of cerebral small- vessel disease: white matter 
hyperintensities (a score of ≥1 on the Fazekas scale), 
CMBs, lacunar infarcts, and superficial siderosis by an 
experienced neuroradiologist (JM). For each partici-
pant, the assessment was repeated three times by the 
same neuroradiologist, who was blinded to all clinical 
data except for whether the participant had diabetes.6 
For analysis, any cerebral small- vessel disease was catego-
rized as presence versus absence of any signs. Further-
more, different manifestations of cerebral small- vessel 
disease were analyzed separately as categorical variables 
(eg, presence vs absence of specific manifestation). 
Participants with CMBs were further categorized based 
on the number of microbleeds as follows: 0 microbleed, 
1–2 microbleeds, and >2 microbleeds.
We performed diabetic retinopathy grading based on 
fundus images, 87% of which were taken within 1 year 
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from the brain MRI. Of the participants with type 1 
diabetes, fundus images were available for 179, and for 
10 participants we were able to make reliable evalua-
tions based on the participants’ medical records. Fundus 
images were available for 29 of the controls. Fundus 
images of both eyes of the participants were evaluated by 
an experienced ophthalmologist (PS), who was blinded 
to the clinical data, but not to whether the participant 
had diabetes or not. Severity of diabetic retinopathy was 
graded according to the ETDRS severity scale,21 22 and the 
grade of the eye presenting more severe diabetic retinop-
athy was used for the analysis. For those having under-
gone scatter photocoagulation, the severity of diabetic 
retinopathy that indicated the treatment was used as the 
grade, that is, the most severe lifetime diabetic retinop-
athy. For analysis, participants were categorized based on 
diabetic retinopathy severity: ETDRS score ≤35 indicating 
no to mild retinopathy, 43–57 moderate to severe non- 
PDR (NPDR), and ETDRS score ≥61 representing PDR. 
Presence of diabetic retinopathy was defined as ETDRS 
scores ≥20. Diabetic retinopathy severity was analyzed in 
relation to cerebral small- vessel disease by retinopathy 
categories as well as by the entire scale.
Statistical analyses
For analysis of continuous parametric variables, we used 
the t- test with results presented as mean±SD, and for 
non- parametric variables the Mann- Whitney U test with 
results presented as median (IQR). In analysis of ordinal 
non- parametric variables, we used the Kruskal- Wallis H 
test with central tendency presented as median (IQR). 
To compare categorical variables between groups, we 
used the Χ2 test and Fisher’s exact test when expected 
frequencies were <5. We used multiple logistic regression 
to analyze the relationship between cerebral small- vessel 
disease and diabetic retinopathy. Cerebral small- vessel 
disease and its different manifestations were analyzed as 
dependent variables in separate models, with diabetic 
retinopathy and clinical confounders as independent 
variables. Results are presented as ORs with 95% CI. 
P<0.05 was considered statistically significant. To analyze 
the conditional probability of the prevalence of cerebral 
small- vessel disease at a given severity level of diabetic 
retinopathy, we used positive (PPV) and negative predic-
tive value (NPV) calculations. PPV was calculated as 
PPV=number of true positives/number of positive calls, 
with ‘true positives’ indicating cases with coinciding 
diabetic retinopathy and cerebral small- vessel disease 
and ‘positive call’ indicating cases with diabetic retinop-
athy regardless of MRI findings. NPV was calculated as 
NPV=number of true negatives/number of negative 
calls, with ‘negative’ indicating no retinopathy and ‘true 
negative’ neither retinopathy nor cerebral small- vessel 
disease. Results are presented as percentages with 95% 
CI. Analyses were performed with the IBM SPSS Statistics 
V.22 software (International Business Machines Corpora-
tion) and R V.4.0.0.
RESULTS
Diabetic retinopathy was present in 155 (82%) of the 
participants with type 1 diabetes. No to mild diabetic reti-
nopathy (ETDRS score ≤35) was observed in 137 (72%) 
participants, moderate to severe NPDR (ETDRS score 
43–57) in 23 (12%), and PDR (ETDRS score ≥61) in 
29 (15%) participants. All 29 participants with PDR, 11 
(48%) with moderate to very severe NPDR, and 4 (4%) 
with very mild or mild diabetic retinopathy had received 
laser photocoagulation, altogether 44 participants. 
Table 1 presents the clinical characteristics of partici-
pants with type 1 diabetes based on severity of diabetic 
retinopathy.
In the participants with type 1 diabetes, cerebral small- 
vessel disease was observed in 67 (35%), CMBs in 45 
(24%), white matter hyperintensities in 44 (23%), and 
lacunar infarcts in 4 (2%). Superficial siderosis was not 
observed in any of the participants. Of the controls, only 3 
(10%) had cerebral small- vessel disease, and 1 individual 
(3%) had one microaneurysm in one eye (corresponding 
to an ETDRS score of 20), whereas 28 individuals exhib-
ited no retinopathy- like abnormalities. None of the 
controls with cerebral small- vessel disease showed any 
signs of pathologies in the fundus images, and associa-
tions between small- vessel disease and retinopathy were, 
thus, not further analyzed in healthy controls.
Participants with type 1 diabetes and cerebral small- 
vessel disease had higher ETDRS scores (35 (20–61) vs 
20 (20–35), p=0.022) and a higher prevalence of PDR 
(25% vs 9%, p=0.002) than those without small- vessel 
disease. In multivariable logistic regression analysis, PDR 
was associated with cerebral small- vessel disease (OR 2.57 
(95% CI 1.04 to 6.35)) after adjustment for age, systolic 
blood pressure, albuminuria, and HbA1c. The entire 
ETDRS scale as a variable, was however, not associated 
with cerebral small- vessel disease after adjustment for the 
same confounders.
In the analysis stratified by the presence or absence of 
diabetic retinopathy (ETDRS ≥20 vs <20), we observed 
no association between cerebral small- vessel disease 
and diabetic retinopathy in those with type 1 diabetes 
(p=0.677). Cerebral small- vessel disease was more prev-
alent (26 (50%) vs 41 (30%), p=0.010) in participants 
with ETDRS score >35 compared with those with ETDRS 
score ≤35. The same was true for ETDRS score >47 vs ≤47 
(19 (50%) vs 48 (32%), p=0.036). When calculating the 
predictive values of ETDRS >35 for cerebral small- vessel 
disease within the cohort, PPV was 50% (95% CI 36% to 
64%) and NPV 70% (62% to 78%).
For the different manifestations of cerebral small- vessel 
disease, we observed a higher prevalence (21 (40%) vs 24 
(18%), p=0.001) and number (p=0.008) of CMBs in those 
with ETDRS score >35 than in those with ≤35. The same 
was seen for ETDRS score >47 compared with ETDRS 
≤47 (15 (40%) vs 30 (20%), p=0.011 and p=0.004, respec-
tively). PPV of ETDRS score >35 was 40% (95% CI 27% to 
54%) and NPV 82% (76% to 89%). No association with 
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cerebral small- vessel disease emerged for white matter 
hyperintensities (prevalence 25% vs 23%, p=0.730 when 
ETDRS >35 vs ≤35% and 29% vs 22%, p=0.355 when 
ETDRS >47 vs ≤47) or for lacunar infarcts (prevalence 
4% vs 2%, p=0.304 when ETDRS >35 vs ≤35, and 5% vs 
1%, p=0.181 when ETDRS >47 vs ≤47).
In participants with CMBs compared with those 
without, we observed a higher median ETDRS score (35 
(20–65) vs 20 (20–35), p=0.024) and a higher prevalence 
of PDR (29% vs 13%, p=0.002). ETDRS scores increased 
by number of CMBs, and the median score was 20 (IQR: 
20–35) in those with 0 CMB, 20 (20–45) in those with 1–2 
Table 1 Clinical characteristics of healthy controls and individuals with type 1 diabetes by retinopathy severity
Healthy controls, 
N=29







Female sex, n (%) 16 (55.2) 75 (54.7) 0.966 8 (34.8) 0.076 17 (58.6) 0.703
Age, years 37.7 (31.3–43.4) 39.8 (32.6–44.3) 0.602 39.4 (34.4–45.6) 0.493 41.5 (35.3–47.6) 0.158
Diabetes duration, 
years
– 20.4 (14.4–26.7) – 22.3 (19.9–29.2) 0.061 35.8 (27.9–37.8) <0.001
BMI, kg/m2 24.4 (22.1–26.1) 25.7 (23.6–28.5) 0.032 28.9 (25.8–31.0) 0.004 27.1 (23.9–30.1) 0.087
Systolic blood 
pressure, mm Hg
121 (112–130) 129 (118–138) 0.004 136 (122–144) 0.062 132 (121–148) 0.195
Diastolic blood 
pressure, mm Hg












Creatinine, µmol/L 74 (67–81) 66 (61–77) 0.019 69 (60–79) 0.537 77 (63–90) 0.009
Total cholesterol, 
mmol/L
4.6 (4.2–5.4) 4.3 (4.0–4.9) 0.145 4.4 (3.8–5.5) 0.649 4.8 (4.0–5.2) 0.055
LDL- cholesterol, 
mmol/L
2.6 (2.3–3.3) 2.4 (2.0–2.8) 0.028 2.5 (2.0–3.0) 0.714 2.4 (2.0–3.0) 0.629
HDL- cholesterol, 
mmol/L
1.45 (1.23–1.66) 1.48 (1.25–1.82) 0.303 1.30 (1.15–1.80) 0.153 1.56 (1.40–1.78) 0.174
Triglycerides, 
mmol/L
0.84 (0.68–1. 27) 0.84 (0.64–1.21) 0.997 1.18 (0.88–2.29) 0.003 1.01 (0.82–1.51) 0.021
Antihypertensive 
medication, n (%)
0 32 (23.4) 0.004 13 (56.5) 0.001 22 (75.9) <0.001
Lipid- lowering 
medication, n (%)
0 20 (14.6) 0.028 11 (47.8) <0.001 10 (34.5) 0.011
Aspirin therapy, n 
(%)
0 8 (5.8) 0.182 2 (8.7) 0.638 4 (14.8) 0.226
Albuminuria, n (%) 0 8 (5.8) 0.182 9 (39.1) <0.001 12 (41.4) <0.001
Cerebral small- 
vessel disease, n 
(%)




2 (6.9) 31 (22.6) 0.054 3 (13.0) 0.298 10 (34.5) 0.179
Microbleeds, n (%) 1 (3.9) 24 (17.5) 0.030 8 (34.8) 0.087 13 (44.8) 0.001
Number of 
microbleeds
0 (0–0) (0–1) 0 (0–0) (0–16) 0.053 0 (0–1) (0–75) 0.035 0 (0–3) (0–105) <0.001
Lacunar infarcts, 
n (%)
0 2 (1.5) 0.513 0 >0.999 2 (6.9) 0.141
Data are presented as median (IQR) (maximum–minimum) or number (%). No or mild DR indicates an Early Treatment Diabetic 
Retinopathy Study (ETDRS) score ≤35; moderate to severe NPDR, ETDRS score 43–57; and PDR, ETDRS score ≥61.
*Participants with no or mild DR compared with controls.
†Participants with moderate to severe NPDR compared with no or mild DR, controls excluded.
‡Participants with PDR compared with no or mild DR, controls excluded.
BMI, body mass index; DR, diabetic retinopathy; HbA1c, glycated hemoglobin; HDL, high- density lipoprotein; LDL, low- density 
lipoprotein; NPDR, non- proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy.
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CMBs, and 63 (43–71) in those with >2 CMBs (p=0.001). 
Figure 1 presents distributions of ETDRS scores by 
number of microbleeds. An independent association 
with >2 CMBs compared with ≤2 was found for both the 
ETDRS score (OR 1.05 (95% CI 1.02 to 1.09)) and PDR 
(OR 8.52 (95% CI 1.91 to 37.94)) in separate analyses 
adjusted for age, systolic blood pressure, albuminuria, 
and HbA1c. When calculating the predictive values of 
ETDRS >35 for the prevalence of >2 microbleeds within 
the cohort, the PPV was 19% (95% CI 9% to 30%) and 
the NPV 99% (97% to 100%). The PPV and NPV of PDR 
were 25% (95% CI 8% to 42%) and 96% (94% to 99%), 
respectively. No association was observed between the 
number of white matter hyperintensities and ETDRS 
score or PDR (data not shown). Due to the low number 
of cases with lacunar infarcts (four participants), we were 
not able to study the association between lacunar infarcts 
and ETDRS score further.
DISCUSSION
This study shows that cerebral small- vessel disease, 
particularly microbleeds, is associated with the severity 
of diabetic retinopathy. The presence of cerebral small- 
vessel disease was associated with an ETDRS score ≥61 
(PDR) after adjustment for confounders. Furthermore, 
as a novel finding, we found the number of microbleeds 
to increase with the ETDRS score. This observation could 
indicate a connection between the severity of asymptom-
atic cerebrovascular disease and the severity of diabetic 
retinopathy in type 1 diabetes.
PDR or severe diabetic retinopathy, indicated by laser 
treatment of the retina, has previously been assessed in 
relation to markers of cerebral small- vessel disease in 
type 1 diabetes.8 16 In accordance with our study, CMBs 
have previously been associated with PDR in a study by 
Woerdeman et al.8 Moreover, severe diabetic retinopathy 
has been reported as an independent risk factor for cere-
bral hemorrhage, as well as for lacunar infarction.16 17 
Although our study confirmed an association between 
PDR and the presence of cerebral small- vessel disease 
(white matter hyperintensities, microbleeds, and/or 
lacunar infarcts), we did not observe any associations 
between diabetic retinopathy and white matter hyperin-
tensities or lacunar infarcts in the analyses of the separate 
manifestations. It is possible that this could be a result of 
the different manifestations having different etiologies. 
Indeed, differences in pathological features of cerebral 
small- vessel disease have previously been described in 
the general population.4 Our negative findings on white 
matter hyperintensities and lacunar infarcts might also 
be a result of the relatively low prevalence of these find-
ings, especially lacunar infarcts, in the current cohort, 
regardless of being a uniquely large cohort of brain MRI 
in type 1 diabetes.
The association between white matter hyperintensities 
and diabetic retinopathy has previously been assessed 
in individuals with type 2 diabetes by Sanahuja et al, 
who observed an association between cerebral small- 
vessel disease and diabetic retinopathy, but not between 
diabetic retinopathy and white matter hyperintensities 
or lacunar infarctions analyzed separately.14 Our obser-
vations are in agreement with these findings; however, 
in contrast to the aforesaid study, our participants were 
21 years younger, by the median. Cerebral small- vessel 
disease has mostly been studied in elderly people without 
diabetes, and is a condition proposed to relate to ageing,4 
however, in type 1 diabetes, cerebral small- vessel disease 
is common already in younger individuals.6 In line with 
our observations, Woerdeman et al also found PDR to 
be associated with cerebral small- vessel disease in young 
individuals. However, the association between age and 
cerebral small- vessel disease was not further elucidated 
in their study. In our current study, we found PDR to be 
associated with cerebral small- vessel disease even after 
adjustment for age, which has not been indicated in 
previous studies.
As a novel finding, we observed a significant increase in 
CMBs at a moderate level of diabetic retinopathy severity. 
We found participants with ETDRS score >35, compared 
with ≤35, to have a higher prevalence and number of 
CMBs. This could indicate that progression from mild 
diabetic retinopathy (ETDRS score ≤35) is associated 
with an increased risk of cerebrovascular disease even 
before new vessel formation (PDR) is manifested. That 
is, when diabetic retinopathy has progressed from very 
mild or mild (microaneurysms only or typically addi-
tional small hemorrhages), to moderate or more severe 
retinopathy (more widespread changes in the retina indi-
cated by larger hemorrhages, intraretinal microvascular 
abnormalities and/or venous beading), it already reflects 
permanent capillary damage, which correlate with an 
increased risk of cerebrovascular disease.
Although severe diabetic retinopathy has previously 
been reported to be independently associated with 
CMBs and cerebral hemorrhage,8 16 to our knowledge 





 >2 CMB 
 N=12
0 25 50 75 100
Distribution of ETDRS scores (%)
10 20 35 47 61 75 85
ETDRS score
Figure 1 Stacked bar plot of Early Treatment Diabetic 
Retinopathy Study (ETDRS) score distribution grouped by 
number of cerebral microbleeds (CMB).
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diabetic retinopathy and cerebrovascular disease in type 
1 diabetes.
In the analyses of the predictive values of the ETDRS 
score within the cohort, the PPV of ETDRS score >35 was 
low (19%) for the prevalence of >2 microbleeds. The 
NPV, however, was high (99%), indicating that within our 
cohort, the probability of having >2 microbleeds was low 
when ETDRS score was ≤35. Although a low ETDRS score 
excluded the presence of multiple microbleeds within 
the current cohort, the study setting did not allow further 
analysis of to what extent the ETDRS score could predict 
CMBs or other manifestations of small- vessel disease in a 
longitudinal setting.
We have previously showed an association between cere-
bral small- vessel disease and systolic blood pressure.6 23 
In the present study, we found the severity of diabetic 
retinopathy (graded by ETDRS scale) to be significant 
after adjustment for systolic blood pressure, indicating 
that, beyond blood pressure, moderate or more severe 
diabetic retinopathy (ETDRS >35) is independently 
associated with cerebral small- vessel disease. However, it 
should be considered that elevated blood pressure and 
diabetic retinopathy are linked24 and due to the cross- 
sectional design of this study, we cannot draw any conclu-
sions about potential causality of the association between 
diabetic retinopathy and small- vessel disease and their 
risk factors. As Woerdeman et al previously stated, diabetic 
retinopathy appears to represent a generalized state of 
microangiopathy.8
The strength of our study is the well- characterized study 
cohort, age- matched and sex- matched healthy controls, 
and standardized imaging and assessment of both brain 
and retinal images. A limitation of our study is the cross- 
sectional study design, which limits the interpretations of 
causal relationships. To our knowledge, our study is the 
largest on cerebral small- vessel disease in type 1 diabetes, 
yet we were not able to do more comprehensive analysis 
of the burden of cerebral small- vessel disease due to the 
low number of certain manifestations.
SUMMARY
In this study, we conclude that cerebral small- vessel 
disease is associated with the severity of diabetic retinop-
athy in type 1 diabetes. Although our results indicate that 
fundus imaging results could also serve as a means of 
identifying individuals at greater risk of cerebrovascular 
complications, further investigations are needed to prove 
or rule out diabetic retinopathy as a predictor of cerebral 
small- vessel disease.
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